Market Cap : 216.85 M | Enterprise Value : 148.69 M | PE Ratio : At Loss | PB Ratio : 2.74 |
---|
NAS:VTGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:VTGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. VistaGen Therapeutics's net income for the three months ended in Dec. 2021 was $-10.54 Mil. Its net income for the trailing twelve months (TTM) ended in Dec. 2021 was $-37.29 Mil.
Net Income is linked to the most popular Earnings per Share (Diluted) number. VistaGen Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2021 was $-0.05.
The historical data trend for VistaGen Therapeutics's Net Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.
Net Income
= Revenue
- Cost of Goods Sold
- Selling, General, & Admin. Expense
- Research & Development
- Depreciation, Depletion and Amortization
- Interest Expense
- Non Operating Income (NRI) - Tax Expense + Others
= EBITDA
- Depreciation, Depletion and Amortization
- Interest Expense
- Non Operating Income (NRI) - Tax Expense + Others
= Operating Income
- Interest Expense
- Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others
VistaGen Therapeutics's Net Income for the fiscal year that ended in Mar. 2021 is calculated as
Net Income | (A: Mar. 2021 ) | ||||||
= | Pre-Tax Income | + | Tax Provision | + | Net Income (Discontinued Operations) | + | Others |
= | -17.932 | + | -0.003 | + | 0 | + | 0.00099999999999767 |
= | -17.93 |
VistaGen Therapeutics's Net Income for the quarter that ended in Dec. 2021 is calculated as
Net Income | (Q: Dec. 2021 ) | ||||||
= | Pre-Tax Income | + | Tax Provision | + | Net Income (Discontinued Operations) | + | Others |
= | -10.535 | + | 0 | + | 0 | + | 0 |
= | -10.54 |
Net Income for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Net income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:
VistaGen Therapeutics's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2021 is calculated as
Earnings per Share (Diluted) (Q: Dec. 2021 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-10.535 | - | 0.208) | / | 202.329 | |
= | -0.05 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
EPS is most useful for companies that have:
A predictable businessThe dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Thank you for viewing the detailed overview of VistaGen Therapeutics's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Saxe Jon S | director | FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076 |
Dotson Jerrold Duane | officer: VP, CFO AND SECRETARY | 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035 |
Singh Shawn | director, officer: CHIEF EXECUTIVE OFFICER | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Snodgrass H. Ralph | director, officer: PRES./CHIEF SCIENTIFIC OFFICER | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Smith Mark Alan | officer: CHIEF MEDICAL OFFICER | 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Mcpartland Mark A. | officer: VP CORPORATE DEVELOPMENT | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Gin Jerry B | director | 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080 |
Underdown Brian J. | director | C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000 |
Cunningham Ann Michelle | director | 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335 |
Rice A. Franklin | officer: VP CORPORATE DEVELOPMENT | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Bonfiglio Gregory A. | director | 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080 |
Platinum Long Term Growth Vii, Llc | 10 percent owner | 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 |
Cato Holding Co | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Cato Allen Easley | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Jones Stephanie | director, 10 percent owner, officer: PRESIDENT | 13834 W. HOYT ROAD RATHDRUM ID 83858 |
From GuruFocus
Other Sources
By Zacks 2021-02-11
By Fool 2021-06-30
By Seekingalpha 2021-11-10
By tipranks.com 2022-03-03
By Zacks 2021-10-20
By Zacks 2021-11-10
By Zacks 2022-02-10
By tipranks.com 2022-02-13
By Zacks 2022-04-05
By Seekingalpha 2022-02-10
By Seekingalpha 2021-01-24
By Zacks 2021-06-16